Year DatePresenter

Title

YearVolPage

2019 4/2

藤岡

Genetic heterogeneity of cytogenetically normal AML with mutations
Blood Advof CEBPA2018

22724-2731

4/19

長井

Pharmacologic control of CAR-T cell function using dasatinib

20193711-717

千綿

Azacitidine maintenance after intensive chemotherapy improves DFS
Bloodin older AML patients

2019

133

1457-1464

田口

The genetic basis and cell of origin of mixed phenotype acuteleukaemia

Nture

2018

562

373-379

クリクラ

Venetoclax Combined With Low-Dose Cytarabine for Previously
Untreated Patients With Acute Myeloid Leukemia: Results From a
Phase Ib/II Study

J Clin Oncol

2019

Epub千綿Allogeneic stem cell transplantation for chronic myeloid leukemia inthe TKI era: population-based data from the Swedish CML registryBone Marrow
Transplant

2019

Epub澤山Combination Lenalidomide and Azacitidine: A Novel Salvage
Therapy in Patients Who Relapse After Allogeneic Stem-Cell
Transplantation for Acute Myeloid Leukemia

J Clin Oncol

2019

37580-588

山田The outcome and characteristics of patients with relapsed adult T cellleukemia/lymphoma after allogeneic hematopoietic stem cell
Hematol Oncoltransplantation

20183754-61

宮崎

Managing Clonal Hematopoiesis in Patients With Solid Tumors

J Clin Oncol

2018

37711

クリクラ

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab
Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent
Lymphoma

J Clin Oncol

2019371188-1199

桐野A Phase 2 Study of Pembrolizumab during Lymphodepletion after
Biol Blood Marrow T
2019Autologous Hematopoietic Cell Transplantation for Multiple Myeloma ransplant

児嶋Chemotherapy-Free Initial Treatment of Advanced Indolent
Lymphoma Has Durable Effect With Low Toxicity: Results From TwoJ Clin Oncol
Nordic Lymphoma Group Trials With More Than 10 Years of FollowUp

2018363315-3325

安藤Targeting an RNA-Binding Protein Network in Acute Myeloid
Leukemia.

Cancer Cell

2019

35369-385

新山

A revised international prognostic score system for Waldenström'smacroglobulinemia.

Leukemia

2019

佐藤Daratumumab plus Lenalidomide and Dexamethasone for UntreatedMyeloma.

N Engl J Med

2019

藤岡

Clonal selection with Ras pathway activation mediates secondary
clinical resistance to selective FLT3 inhibition in acute myeloid
leukemia.

Cancer Discov2019

波多Clonal evolution patterns in acute myeloid leukemia with NPM1mutation.

Nat commun

2019

10(1)

2031

クリクラ

Polatuzumab vedotin in combination with immunochemotherapy inpatients with previously untreated diffuse large B-cell lymphoma: an
open-label, non-randomised, phase 1b-2 study.

Lancet Oncol

2019

20(7)

998-1010

坂本

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, andcyclophosphamide; tacrolimus, methotrexate, and bortezomib; ortacrolimus, methotrexate, and maraviroc) versus tacrolimus andmethotrexate for prevention of graft-versus-host disease withLancet Haematol
haemopoietic cell transplantation with reduced-intensity conditioning:a randomised phase 2 trial with a non-randomised contemporaneouscontrol group (BMT CTN 1203).

2019

6(3)

e132-e143

長井

Bone marrow central memory and memory stem T-cell exhaustion in
AML patients relapsing after HSCT.

2019

10(1)

1065

4/16

5/7

5/14

5/21

5/28

6/4

6/11

6/18

6/25

JournalBlood Adv

Nat commun

Epub

Epub
222104-2155

Epub